HearnJayChoMD

PubMed

• MRD-negative duration following latest line of therapy predicts long-term PFS in real-world multiple myeloma patients.
  Lucia Y Chen, Santiago Thibaud, Saoirse Bodnar, Ajai Chari, Joshua Richter
  Blood Advances. 2024-11-15
• Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.
  Santiago Thibaud, Ryan L Subaran, Scott Newman, Alessandro Lagana, David T Melnekoff
  Blood Cancer Discovery. 2024-11-01
• Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma.
  Anna Huo-Chang Mei, Alessandro Laganà, Roman Osman, Hearn Jay Cho
  Seminars in Hematology. 2024-10-28

Abstracts/Posters

• Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
  Hearn Jay Cho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma
  Hearn Jay Cho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes
  Hearn Jay Cho, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018